The study of the effect of growth hormone adjuvant therapy on ICSI trials for poor ovarian reserve patients

illustrative image

Beni-Suef University is enrolling patients into the clinical trial investigating Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials.

The trial is designed to enroll Female 20 Years to 40 Years and is being conducted in the Beni-suef university, Banī Suwayf, Beni Suef, Egypt.

The study start date is February 1, 2022, and it is planned to enroll 120 participants.

The patients that have antral follicle count (AFC)<7 or - anti-Müllerian hormone (AMH)<1.1ng/ml may be included into this study.

Whereas the following patients will be excluded from participation: with any known contraindications to the approved fertility drugs, any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment), Hydrosalpinx, uterine malformations or abnormal uterine cavity, basal FSH more than 17 IU, abnormal karyotyping, with partner with severe male factor, and/or with uncontrolled endocrinopathies (DM, hyperthyroidism, hypothyroidism).

This page provides a more detailed overview of this clinical trial:

Clinical Research News

Upcoming Clinical Trials